mgcd0103
Mgcd0103 is a drug used to treat Myelodysplastic Syndromes, Leukemia, Tumors, and other conditions. Mgcd0103 is not being actively studied and prior, has been studied in 7.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Mirati Therapeutics Inc. | MD Anderson Cancer Center | |
| Gabrail Cancer Center | ||
| Princess Margaret Hospital |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Terminated
- Hodgkin's Lymphoma
- MGCD0103
- Chicago, Illinois
- +4 more
2015-06-05
Jun 5, 2015M
Completed
- Lymphoma
- MGCD0103
- Durham, North Carolina
- +4 more
2015-06-04
Jun 4, 2015M
M
Completed
- Myelodysplastic Syndrome
- Acute Myelogenous Leukemia
- MGCD0103
- Los Angeles, California
- +7 more
2015-06-04
Jun 4, 2015M
Completed
- Lymphocytic Leukemia, Chronic
- MGCD0103
- Kansas City, Missouri
- +12 more
2015-06-04
Jun 4, 2015M
Terminated
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)
- Azacitidine
- MGCD0103
- Houston, Texas
- +7 more
2015-04-22
Apr 22, 2015M
Terminated
- Myelogenous Leukemia, Acute
- Myelodysplastic Syndromes
- MGCD0103
- Kansas City, Missouri
- +12 more
2015-06-04
Jun 4, 2015M
Completed
- Leukemia
- Myelodysplastic Syndromes
- MGCD0103
- Houston, Texas
- +2 more
2015-01-06
Jan 6, 2015M
Completed
- Tumors
- Non Hodgkin's Lymphoma
- MGCD0103
- Baltimore, Maryland
- +2 more
2015-01-06
Jan 6, 2015M
Completed
- Leukemia
- Myelodysplastic Syndromes
- MGCD0103
- Tampa, Florida
- +3 more
2015-01-06
Jan 6, 2015